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Urinary exosomes or microvesicles are being studied
intensively to identify potential new biomarkers for renal
disease. We sought to identify whether these microvesicles
contain nucleic acids. We isolated microvesicles from human
urine in the same density range as that previously described
for urinary exosomes and found them to have an RNA
integrity profile similar to that of kidney tissue, including 18S
and 28S rRNA. This profile was better preserved in urinary
microvesicles compared with whole cells isolated from urine,
suggesting that microvesicles may protect RNA during urine
passage. We were able to detect mRNA in the human urinary
microvesicles encoding proteins from all regions of the
nephron and the collecting duct. Further, to provide a proof
of principle, we found that microvesicles isolated from the
urine of the V-ATPase B1 subunit knockout mice lacked
mRNA of this subunit while containing a normal amount of
the B2 subunit and aquaporin 2. The microvesicles were
found to be contaminated with extraneous DNA potentially
on their surface; therefore, we developed a rapid and reliable
means to isolate nucleic acids from within urine microvesicles
devoid of this extraneous contamination. Our study provides
an experimental strategy for the routine isolation and use of
urinary microvesicles as a novel and non-invasive source of
nucleic acids to further renal disease biomarker discovery.
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Exosomes are classically formed from the inward invagina-
tion and pinching-off of the late endosomal membrane. This
results in the formation of a multivesicular body (MVB)
laden with small lipid-bilayered vesicles (B40–100 nm in
diameter), each of which contains a sample of the parent
cell’s cytoplasm.1 Fusion of the MVB with the cell membrane
results in the release of these ‘exosomes’ from the cell, and
their delivery into the blood, urine, or other body fluids.
Exosome-like vesicles including ‘shedding microvesicles’2
may also be formed by the budding-off of the cell’s plasma
membrane, and although more heterogeneous in size,2,3 may
also contain a snapshot of the parent cell’s RNA. Although
the majority of microvesicles isolated from urine are thought
to be exosomes,4 both exosomes and other microvesicles do
co-isolate during ultracentrifugation and ultrafiltration iso-
lation techniques and will, therefore, be collectively referred
to as microvesicles here. Recent pioneering oncology research
has shown that exosomes carry mRNA and/or miRNA5–7 that
may encode tumor markers, potentially circumventing the
need for biopsies and highlighting the enormous diagnostic
potential of exosome biology.5
Comprehensive studies have been conducted on the
proteomic analysis of urinary microvesicles, revealing that
they contain a variety of cell-specific proteins/transporters
from the kidney and the urogenital tract.4,8 It was further
shown that urinary microvesicles are very stable, highlighting
their potential use as a reliable urinary marker.9 However,
there have been no in-depth studies analyzing the nature of
nucleic acids within the microvesicles or their reliability as a
source of nucleic acid biomarkers for renal function. Whole
urine is known to contain nucleic acids derived from whole
cells and free DNA.10,11 However, such extraneous nucleic
acids may not be a reliable source of biomarkers as they may
be derived from apoptotic cells, the transcriptional profile of
which may not be representative of a functioning cell.
The investigation of new biomarkers for renal disease is
currently an important and pressing issue, with renal disease
affecting up to 1 in 10 of the US population.12 Urinary
microvesicles may provide a unique means to analyze the
transcriptional profile of the kidney as they are derived from
functioning cells. The isolation of microvesicles usually calls
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for ultracentrifugation, but recent studies have shown that
they may also be rapidly isolated using filtration concen-
trators,13 increasing the potential for their use in routine
diagnostic analysis. Currently, it is not known whether the
use of filtration concentrators would yield intact micro-
vesicles for RNA extraction.
Here we conduct an in-depth analysis of the nucleic acids
associated with urinary microvesicles, including (i) the
potential for extraneous nucleic acid contamination during
urinary microvesicle isolation, (ii) the non-invasive identifi-
cation of renal related transcripts from various regions of the
nephron and collecting duct by reverse transcriptase-PCR
(RT-PCR), (iii) the application of microvesicle derived RNA
analysis in renal pathophysiology, (iv) analysis of RNA
integrity in microvesicles versus whole cells in urine, and (v)
the nucleic acid analysis of isolated microvesicles using
filtration concentrators versus ultracentrifugation. These
studies increase our understanding of urinary microvesicles
and support their potential as a novel source of new and
much needed biomarkers for renal disease analysis.
RESULTS
Figure 1a shows transmission electron microscope images of
MVBs present in rat renal tissue. This shows that exosomes
can indeed be released from various regions of the nephron,
as well as from both intercalated and principal cells of the
collecting duct. Using transmission electron microscopy we
also examined the pellet isolated by differential centrifugation
to show that the pellet was indeed rich in microvesicles
(Figure 1b). To ensure that the RNA was coming from
microvesicles and not large membrane blebs, a Percoll
gradient was used to separate the pelleted microvesicles
based on density (Figure 1c) and RNA was extracted from
each fraction. Results revealed that the RNA obtained was
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Figure 1 | Electron microscopy of urinary microvesicles. (a) Multivesicular bodies (MVBs) can be identified in various regions of the
nephron and collecting duct (see arrows). Bar ¼ 200 nm for A, C, D, E, F; 500 nm for B. (b) Human urinary microvesicles isolated using
differential ultracentrifugation and imaged via transmission electron microscopy using phosphotungstic acid as a stain. Bar ¼ 200 nm.
(c) Percoll gradient analysis of urinary microvesicles shows that RNA-containing microvesicles are within the density range for urinary
microvesicles previously characterized as exosomes. CD-IC, collecting duct intercalated cell; CD-PC, collecting duct principal cell; Podo,
podocyte; PT, proximal tubule; TAL, thick ascending limb; TDL, thin descending limb.
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indeed coming from microvesicles within the same density
range as that previously described for urinary exosomes.14
Using differential centrifugation in combination with
RNase and DNase digestion of the microvesicle pellet, we
determined whether extraneous nucleic acids may co-isolate
with urinary microvesicles. Results revealed that extraneous
DNA (that is, free DNA) contaminates isolated urinary
microvesicles (Figure 2a) and serum-derived microvesicles
(see Supplementary Figure S1d). The level of extraneous
DNA varied between subjects but was consistently shown to
be predominantly in the range ofB25–1500 nucleotides (nt).
In contrast, no obvious extraneous RNA could be detected
(Figure 2b), consistent with the presence of ribonucleases in
urine.15 Analysis of the nucleic acids within microvesicles
revealed some striking features, including the presence of
prominent 18S and 28S rRNA peaks similar to those seen for
RNA isolated from rat kidney tissue (Figure 2c). Such rRNA
was not prevalent in previously reported serum-derived or
cell culture-derived microvesicles, although they may be
detectable depending on isolation technique as shown in the
serum RNA isolation profile in Supplementary Figure S1d.
Both urinary microvesicles and kidney tissue also contained
small RNAs when miRNA isolation methods were used
(Figure 2d) as previously reported.16 Various extraction kits
are available for the isolation of RNA and removal of DNA. A
comparative analysis of RNeasy Qiagen kits and the acid
phenol/chloroform-based mirVana kit is shown in Supple-
mentary Figure S1.
To determine the nucleic acid content within urinary
microvesicles, the pellets were subjected to RNase and DNase
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Figure 2 |Analysis of nucleic acids associated with urinary microvesicles using the Agilent Bioanalyzer. (a) Plot showing that
microvesicles may co-isolate with extraneous DNA that can be removed by DNase digestion of the microvesicle pellet prior to lysis and
nucleic acid extraction. Red — profile without DNase digestion, blue — profile with DNase digestion. (b) Plot showing that microvesicles do
not co-isolate with detectable levels of extraneous RNA. Red — without RNase digestion, blue — with RNase digestion. (c) RNA isolated
from rat kidney (red) and microvesicles (blue) exhibited a very similar profile, including the presence of 18S and 28S rRNA peaks. Both
samples underwent processing using the RNeasy Plus Micro kit to remove genomic DNA (gDNA) contamination. (d) Urinary microvesicles
contain a prominent ‘small RNA’ peak (between 25–200 nt) when miRNA isolation techniques are used. Red — kidney RNA isolated using
RNeasy Plus Micro kit using the miRNA extraction method, blue — microvesicle RNA isolated with RNeasy Plus Micro kit using the miRNA
extraction method. (e) Nucleic acids were isolated from microvesicles that had undergone RNase and DNase digestion on the outside before
microvesicle lysis. During RNA extraction using the RNeasy Micro kit, half of the samples underwent on-column RNase digestion (see
Materials and methods) while the other half underwent the same on-column incubation without the presence of RNase. Results revealed
that RNase digestion was able to remove the majority of the profile, suggesting that RNA is the major nucleic acid within urinary
microvesicles. Red — nucleic acid profile without intra-microvesicular RNase digestion, blue — nucleic acid profile with intra-microvesicular
RNase digestion. (f) Further digestion with DNase following RNase digestion revealed that the remaining peak could be further reduced,
suggesting that some material prone to DNase digestion remained in the sample potentially representing intra-exosomal DNA. Red — nucleic
acid profile following intra-microvesicular on-column RNase digestion alone, blue — nucleic acid profile following both intra-microvesicular
on-column RNase and DNase digestion. 18S and 28S rRNA peaks are indicated in (a). The peak at 25 nt represents an internal standard.
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digestion to remove extraneous contamination, followed by
RNase and/or DNase digestion of intra-microvesicular
nucleic acids during column-based nucleic acid isolation.
On-column RNase digestion almost completely abolished
the nucleic acid profile (Figure 2e), suggesting that RNA
represents the most abundant nucleic acid within micro-
vesicles. Further, on-column digestion with DNase revealed
that the remaining peak could be further decreased,
suggesting that there may be some DNase digestible material
within microvesicles (Figure 2f).
To further determine whether microvesicles contain
mRNA transcripts encoding markers from various nephron
and collecting duct segments, RNA isolated from urinary
microvesicles of four human controls (23–32 years of age)
was subjected to RT-PCR. Both glyceraldehyde 3-phosphate
dehydrogenase and b-actin genes were identified in all
samples (Figure 3a). Next we examined 15 transcripts
characteristic of various regions of the nephron and
collecting duct (Figure 3b). These included proteins and
receptors implicated in various renal diseases: podocin from
the glomerulus, cubilin from the proximal tubule, and
aquaporin 2 from the collecting duct. Genes from all regions
examined could be identified, consistent with the results
obtained in Figure 1a. This shows that microvesicles
containing mRNA are released from all regions of the
nephron and the collecting duct and are, therefore, a novel
non-invasive source of potential nucleic acid biomarkers for
renal disease.
To test the hypothesis that microvesicles may be used to
non-invasively examine renal genes in disease, the V-ATPase
B1 subunit knockout mouse model of renal acidosis was
used.17 Figure 4 shows that expression of the V-ATPase B1
subunit and aquaporin 2 mRNA can be examined non-
invasively in the microvesicles using RT-PCR (Figure 4a). In
addition, real-time PCR was used to quantitatively examine
the expression of the V-ATPase B2 subunit. The renal
expression of the V-ATPase B2 subunit is the same in
V-ATPase B1 / animals as in V-ATPase B1 þ /þ mice
(Figure 4b) despite the loss of the B1 subunit, confirming the
results obtained for the corresponding kidneys as well as
previously reported data.18
Although mRNA transcripts can be isolated from urinary
microvesicles, which are devoid of extraneous DNA and
RNA, what advantage does this mRNA source have over RNA
derived from cells and cell debris in the urine? To examine
this, we utilized a ‘whole’ urine RNA extraction kit (see
Materials and methods) and compared the RNA profile with
that obtained from microvesicles in the same sample. A large
amount of nucleic acid could be isolated using the ZR urine
RNA isolation kit (Figure 5a), the majority of which was
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Figure 3 |Urinary microvesicles contain messenger RNA (mRNA) transcripts encoding specific genes from various regions of the
nephron and the collecting duct. (a) Bioanalyzer-generated ‘Pseudo gel’ profiles of the positive identification of RiboAmp-amplified mRNA
transcripts for b-actin (ACTB) and glyceraldehyde 3-phosphate (GAPDH) in urinary microvesicles from four subjects by RT-PCR. (b) Cartoon of
the nephron and collecting duct highlighting its functionally distinct regions. (c) The positive identification of (1) Glomerulus: NPHS2 —
podocin, LGALS1 — Galectin-1, HSPG2 — heparan sulfate proteoglycan; (2) proximal tubule: CUBN — cubilin, LRP2 — megalin, AQP1 —
aquaporin 1, CA4 — carbonic anhydrase 4, CLCN5 — chloride channel protein 5, (3) thin descending limb: BDKRB1 — bradykinin B1 receptor;
(4) medullary thick ascending limb: CALCR — calcitonin receptor, SCNN1D — amiloride-sensitive sodium channel subunit delta; (5) distal
convoluted tubule: SLC12A3 — thiazide-sensitive sodium-chloride cotransporter; (6) collecting ducts: AQP2 — aquaporin 2, ATP6V1B1 —
V-ATPase B1 subunit, SLC12A1 — kidney-specific Na–K–Cl symporter via RT-PCR of RiboAmped mRNA from urinary exosomes.
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DNA (Figure 5a). The profile appeared broad and lacked 18S
and 28S rRNA peaks in comparison with that normally
obtained from tissue or from within microvesicles (see Figure
2c), indicating considerable degradation. In contrast, RNA
from microvesicles isolated from the same urine sample had
clearly visible 18S and 28S rRNA peaks, indicating good
quality RNA (Figure 5b). Analysis of the nucleic acid profile
of the various pellets obtained during microvesicle differ-
ential centrifugation revealed that pellets from the 300 g
(Figure 5c) and 17,000 g (Figure 5d) spins exhibited a nucleic
acid profile similar to those obtained from the ZR urine RNA
isolation kit and were, indeed, made up of a large proportion
of DNA (Figure 5c and d, respectively) along with degraded
RNA. This showed that the RNA isolated from urinary cells is
less stable than the RNA isolated from urinary microvesicles.
Although urinary microvesicles seem like a promising
source of renal biomarkers, their isolation by ultracentrifuga-
tion is both time consuming and requires elaborate
equipment. We, therefore, investigated whether filtration
concentrators, previously used to isolate urinary microve-
sicles for protein analysis,13 could yield viable microvesicles
for RNA extraction. To test this, we processed urine samples
up to the 0.8-mm filter step (see Materials and methods) and
compared them with samples processed using a 100 kDa
MWCO filtration concentrator (Millipore, Bedford, MA,
USA) versus ultracentrifugation both with RNase digestion,
and with and without DNase digestion to remove extra-
microvesicular nucleic acid contamination. Results revealed
that the ultracentrifugation method and the filtration
concentration method yielded similar RNA concentrations
from 75 ml urine samples (ultracentrifugation 410±28 pg/ml,
filtration concentrator 381±47 pg/ml mean ± s.d., not
statistically significant) with minimal degradation (Figure 6a),
suggesting that the use of filtration concentrators may be a
reliable method for the isolation of urinary microvesicles
for RNA analysis. Finally, we examined whether the urine
pre-processing steps could be replaced with just a 0.8-mm
filtration step (see Materials and methods). Results using
ultracentrifugation (Figure 6b) and filtration concentrators
(Figure 6c) revealed that the 0.8 mm filtration could indeed
replace the urine pre-processing steps, further decreasing the
isolation time.
DISCUSSION
Currently, renal biomarkers are limited to urinary protein
analysis and changes in the glomerular filtration rate.
Biomarkers at the nucleic acid level are understudied, in
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Figure 4 |Analysis of gene expression by RT-PCR and real-
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Figure 5 |RNA extracted from whole urine cells and debris has
a different RNA profile from that of tissue and urinary
microvesicles. (a) Analysis of RNA isolated from whole urine
(exclusive of microvesicles that are not captured by the isolation
technique) showed that a large yield of nucleic acids can be
isolated (see the red profile). Processing of the isolated nucleic
acids using the RNeasy Plus Micro kit (which removes gDNA)
reveals that the majority of nucleic acids isolated using the ZR
urine RNA isolation kit is DNA and the remaining RNA lacks rRNA
peaks found in tissue and urinary exosomes. Red — nucleic acids
isolated from whole urine without gDNA removal, blue — nucleic
acids isolated from whole urine post gDNA removal using the
RNeasy Plus Micro kit. (b) Isolation of microvesicles from the same
urine sample revealed that the microvesicles retained a normal
total RNA profile suggesting that RNA within whole cells may be
less stable than that contained in urinary microvesicles. Red —
without removal of gDNA, blue — sample processed using the
RNeasy Plus Micro kit to remove contaminating gDNA. (c)
Isolation of nucleic acids from the pellet formed during the 300 g
spin revealed that the nucleic acid profile was different from that
of microvesicles and that it contained a large amount of gDNA
following processing using the RNeasy Plus Micro kit. Red —
nucleic acids isolated from the 300 g pellet without gDNA
removal, blue — nucleic acid isolated from the 300 g pellet post
gDNA removal using the RNeasy Plus Micro kit. (d) Isolation of
nucleic acids from pellets formed during the 17,000 g spin
revealed that the nucleic acid profile was different from that of
microvesicles and that it contained a large amount of gDNA
following processing using the RNeasy Plus Micro kit. Red —
nucleic acids isolated from the 17,000 g pellet without gDNA
removal, blue — nucleic acids isolated from the 17,000 g pellet
post gDNA removal using the RNeasy Plus Micro kit.
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part because this requires the invasive and expensive
procedure of organ biopsy. However, urinary microvesicles
now offer a novel means to obtain this information without
the need for invasive and expensive biopsy procedures,
potentially taking renal biomarker discovery to a new level.
Analysis of extraneous nucleic acid contamination during
urinary microvesicle isolation revealed that there was the
potential for DNA contamination. This could be easily
removed by (i) digestion of the microvesicle pellet with
DNase or (ii) the use of genomic DNA elimination kits such
as the RNeasy Plus Micro kit. External DNase digestion
should now be part of the standard procedure when isolating
microvesicles for nucleic acid analysis. This also appears
to remove DNase-susceptible ‘apoptotic DNA ladder’ like
material, which may contaminate serum microvesicle pellets,
as shown in the Supplementary Data. The finding that there
was no detectable extraneous RNA contamination was not
surprising, because urine contains ribonucleases.15 The fact
that microvesicles can resist RNase and DNase digestion and
still protect the nucleic acids contained within them is quite
remarkable, and adds further support to the previously
reported stable nature of urinary exosomes.9
A potential advantage of carrying out extra-microvesicular
rather than on-column DNase digestion is that it leaves the
nucleic acids within exosomes untouched. This is important,
particularly in cases where potential DNase digestible
material may be captured from the cytoplasm of a cell and
may itself be a source of biomarkers for non-coding
sequences, which are now believed to have a potential role
in cell regulation.19–21 Other studies have also suggested that
mitochondrial DNA is present in exosomes isolated from
astrocytes and glioblastoma cell cultures,22 suggesting that
cancer-related microvesicles may contain mtDNA. Overall,
our studies suggest that microvesicles can be a reliable source
of living cell cytoplasm-derived nucleic acids for biomarker
discovery, and are devoid of extraneous nucleic acids when
processed correctly.
Although urine-derived microvesicles contain an RNA
profile similar to whole tissue including prominent 18S and
28S rRNAs, this rRNA material appears less prevalent in
microvesicles isolated from the serum5–7 and saliva.23 It is not
known whether this is due to differences in microvesicular;
(i) yield, (ii) stability, or (iii) origin (that is, whether the RNA
profile may be different in shedding microvesicles versus
those derived from MVBs) in the various body fluids. A
comparison of RNA sources in urine revealed that rRNA
peaks appeared better preserved in microvesicles versus cells
in urine, suggesting that microvesicles are a reliable source of
stable nucleic acids and that they protect their inner content
which is extremely important for downstream RNA analysis.
Unlike whole cells, microvesicles are quite resistant to
freeze–thawing, and nucleic acids can be extracted from the
urinary exosomes following freeze–thawing (Russo et al.,
unpublished data). This suggests that in frozen archived
samples, microvesicles may also be a more reliable source of
RNA for longitudinal studies than whole cells from urine.
Further, it is not known how release of cells from their
physiological setting (that is, loss of cell–cell and cell–sub-
strate interaction, and local stimuli) affects gene expression in
whole cells found in urine. Urinary microvesicles may also be
considered as a unique source of RNA not only because of
their stable and non-invasive nature, but also because their
RNA represents a snapshot of the whole urinary system. This
is unlike the RNA obtained from renal biopsy, which
represents a small sample from only one of the two kidneys.
The presence of mRNA transcripts encoding renal genes
from various regions of the nephron and the collecting duct
was also confirmed. These transcripts were contained within
microvesicles and were confirmed as mRNA-derived, because
a poly-A tail-specific RNA amplification technique was used.
Many of the genes analyzed are disrupted in various renal
diseases, including podocin in glomerular diseases such as
steroid-resistant nephrotic syndrome,24 cubilin25 associated
with proteinuria in Imerslund–Gra¨sbeck syndrome, and
aquaporin 2 associated with diabetes insipidus.26 To further
highlight the use of microvesicular RNA analysis in renal
pathophysiology, we used both RT-PCR for the mRNA
detection of genes as well as real-time PCR for the relative
quantitation of renal genes expressed in the V-ATPase B1
knockout mouse. The analysis of mRNA in urinary
microvesicles paralleled that obtained in renal tissue from
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Figure 6 | Isolation of microvesicles using filtration
concentrators reveals that this may be a rapid technique
to isolate intact microvesicles for nucleic acid extraction.
(a) A sample of 75 ml human urine was subjected to the initial
processing steps of 300 g, 17,000 g centrifugation followed by
0.8mm filtration and was then processed using ultracentrifugation
(blue) or using 100 kDa MWCO filters (red). The results revealed
that a similar profile was obtained using both extraction methods
with minimal degradation of the RNA revealing that filtration
concentrators may be a fast and reliable way to isolate urinary
microvesicles. Comparison of the ‘normal’ 300 g, 17,000 g spin and
0.8mm filtration steps (red) with just a 0.8 mm filtration step (blue)
followed by (b) ultracentrifugation or (c) filtration concentrators
revealed that the 300 g and 17,000 g spins were not crucial for the
removal of cell debris and whole cells as no change in profile was
observed, further simplifying the isolation technique and the time
taken to isolate exosomes. All samples underwent extra-exosomal
RNase and DNase digestion before microvesicular lysis.
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these mice18 (and this study) and adds support for the use of
urinary microvesicles for pathophysiological analysis.
The use of filtration concentrators to isolate urinary
microvesicles indicates that elaborate ultracentrifugation
steps may not be required for the isolation of microvesicles
for nucleic acid analysis. The use of a 100 kDa MWCO
membrane aided in the removal of DNase I (B39 kDa) and
RNase A (B13.7 kDa) from the sample following extraneous
nucleic acid digestion steps. This rapid isolation technique,
which reduces 70 min centrifugation steps down to 4 min
steps (potentially reducing more than 3.5 h of ultracentrifu-
gation to o30 min in a bench-top centrifuge), is extremely
important for future studies into biomarker discovery and
has the potential to move exosome biology into clinical
laboratories as a routine diagnostic procedure.
In summary, we have shown that urinary microvesicles-
may (i) be complexed with extraneous DNA, highlighting the
importance of DNA removal from the sample before nucleic
acid analysis; (ii) contain mainly RNA, including prominent
18S and 28S rRNA similar to that seen in tissue-derived RNA;
(iii) contain mRNA transcripts representing markers from all
regions of the nephron and the collecting duct, suggesting
that the mRNA contained within them is stable for RT-PCR
analysis; (iv) contain RNA that is more stable than RNA
extracted from whole urine; and (v) be rapidly isolated using
filtration concentrators without significant loss of RNA
integrity, providing a rapid means to isolate microvesicles
without the need for elaborate ultracentrifugation. These
findings pave the way for the use of urinary microvesicles as a
novel source of new and much needed nucleic acid
biomarkers for renal disease.
MATERIALS AND METHODS
Urine pre-processing
Human urine was obtained under the approved instititional review
board guidelines of the Massachusetts General Hospital. Urine pre-
processing by the ‘normal method’ included centrifugation of the
urine at 300 g for 10 min at 4 1C, centrifugation of the supernatant at
17,000 g for 20 min at 4 1C, and filtration of the supernatant through
a 0.8 mm filter (cellulose nitrate membrane filter unit; Nalgene,
Rochester, NY, USA). Alternatively, urine pre-processing using the
‘0.8 mm method’ included filtration of the urine directly through the
0.8mm filter without any pre-centrifugation steps. For analysis of
extraneous nucleic acids B25 ml of duplicate urine samples was
used, and B75 ml duplicates were used for the analysis of intra-
microvesicular nucleic acids. For comparison of the nucleic acid
extraction kits B75 ml of duplicate urine samples was used. For
comparison of the RNA from urinary cells extracted using the ZR
isolation kit, 300 and 17,000 g pellets, and the corresponding RNA
from microvesicles, B75 ml of duplicate urine samples was used.
For analysis of filtration concentrators versus ultracentrifugation,
B75 ml of duplicate urine samples was used. For RT-PCR analysis
200 ml urine samples were used. Urine samples were collected over a
24-h period and stored at 4 1C.
Microvesicular isolation by ultracentrifugation
Following pre-processing, the filtrate underwent ultracentrifugation
at 118,000 g for 70 min at 4 1C; the supernatant was removed and the
microvesicle-containing pellet was washed in phosphate buffered
saline (PBS) and re-pelleted at 118,000 g for 70 min at 4 1C. The
microvesicle pellet was then subjected to RNase and/or DNase
digestion to remove extraneous nucleic acids.
Removal of extraneous nucleic acids
The microvesicle pellet derived from ultracentrifugation was
resuspended in 1 ml per ml RNase A (DNase and protease free,
Fermentas, Glen Burnie, MD, USA) in PBS and incubated for 1 h at
37 1C. The samples were re-pelleted at 118,000 g for 70 min in PBS.
The corresponding urine sample was used as control also incubated
at 37 1C for 1 h in the presence of the RNase inhibitor cocktail
SUPERaseIn (1U/ml) according to the manufacturer’s instructions.
For DNase I digestion the pellet was resuspended in 500ml PBS and
DNase I (RNase free, Qiagen, Valencia, CA, USA) diluted in RDD
buffer (according to manufacturer’s instructions) was incubated at
room temperature for 10 min. The samples were re-pelleted at
118,000 g for 70 min in PBS. For RNase A and DNase I digestion of
microvesicles isolated using filtration concentrators, the same
concentration of RNase and DNase was used and incubations were
carried out in filtration concentrators. RNase A or DNase I was
removed by three resuspension/wash steps with 15 ml of PBS.
Microvesicle isolation using filtration concentrators
Filtration concentrators (100 kDa MWCO, Millipore) were prepared
according to the manufacturer’s instructions. Pre-processed
urine (see above) was added to the filtration concentrator and
centrifuged at 4000 g for 4 min at RT. A wash step with 15 ml PBS
was included. The isolated microvesicles were then subjected to
RNase and/or DNase digestion to remove extraneous nucleic acids
as described above.
Nucleic acid extraction and analysis
Once the microvesicles were isolated and digested with
nucleases, the pellet was processed by the RNeasy Micro kit
(Qiagen) according to the manufacturer’s instructions. In all, 350ml
of RLT buffer (with 10 ml b-mercaptoethanol per ml RLT) was used
to lyse microvesicles and 16 ml of nuclease-free water was used for
elution. The RNeasy Plus Micro kit (Qiagen) is designed to remove
genomic DNA and was used according to the manufacturer’s
instructions and eluted in 16 ml nuclease-free water. For small RNA
isolation using the RNeasy Micro kit or RNeasy Plus Micro kit, the
miRNA isolation method was followed according to the manufac-
turer’s instructions. RNA was isolated from whole urine using the
ZR urine RNA isolation kit (Zymo Research, Orange, CA, USA)
according to the manufacturer’s instructions. To remove genomic
DNA from the Zymo processed sample, the eluted RNA was
resuspended in 350ml RLT buffer and processed using the RNeasy
Plus Micro kit and eluted in 16ml nuclease-free water. Isolated RNA
was analyzed on a RNA Pico 6000 chip (Agilent, Palo Alto, CA, USA)
using an Agilent Bioanalyzer (Agilent), which generated an electro-
phoretic profile and the corresponding ‘pseudo’ gel of the sample.
Percoll gradient analysis of microvesicles
Percoll gradient (Sigma, St Louis, MO, USA) was diluted with 9%
saline to form a 0.9% saline/Percoll solution. Pelleted microvesicles
from a 600 ml urine sample (RNase and DNase treated as described
above) resuspended in 0.5 ml 0.9% saline were gently layered on top
of a 14 ml Percoll saline solution. A corresponding standard tube
was prepared in the same manner except that density standard beads
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(Sigma) were layered on the top. The two tubes were centrifuged at
50,000 g for 45 min. A standard curve was plotted from the gradient
density beads, and the density of each 750 ml fraction removed from
the microvesicle tube was determined. For each fraction, the Percoll
was separated from the microvesicles by centrifugation for 90 min at
118,000 g followed by three subsequent wash steps inB20 ml PBS at
118,000 g for 70 min. RNA was then extracted from each pellet using
the RNeasy Micro kit (Qiagen).
Analysis of nucleic acids within microvesicles
Digestion of nucleic acids within microvesicles was carried out
using on-column RNase A (Fermentas) or DNase I (Qiagen)
digestion in conjunction with the RNeasy Micro kit (Qiagen). In
short, DNA digestion was carried out according to the manufac-
turer’s guidelines using the RNeasy Micro kit (Qiagen). RNA
removal was carried out using the same steps as for DNA digestion
except that 700 ml of RNase A (1 ml per ml RW1 wash buffer) was
incubated on-column for 1 h at 37 1C. Following incubation,
nucleases were removed using RW1 wash steps as outlined in the
manufacturer’s guidelines.
Animal studies
All animal experiments were carried out in accordance with
approved animal ethics guidelines at the Massachusetts General
Hospital. V-ATPase B1 subunit knockout animals have been
previously described.17,18 For urine collection animals were caged
in metabolic cages in groups of two (n¼ 4 animals per group) over a
period of 72 h (sufficient RNA can also be obtained by caging one
animal per cage (Russo et al., unpublished data)) and urine was
collected for microvesicle isolation and analysis as described above
for human urine. For kidney extraction, animals were anesthetized
using pentobarbital sodium (Nembutal) (Abbott Laboratories,
Abbott Park, IL, USA) (65 mg per kg body weight i.p.) and kidneys
immediately removed and frozen in liquid nitrogen. Using a pestle
and mortar in a liquid nitrogen bath, the frozen kidney was ground
up, resuspended in RNAlater (Qiagen) and stored in 1 ml aliquots at
80 1C. For RNA extraction, an aliquot was thawed on ice and 50ml
lysed in 350ml RLT buffer (with 10ml b-mercaptoethanol per ml
RLT). The rat kidney samples were processed using the RNeasy Mini
kit and the RNeasy Plus kit. To determine the amount of small RNAs
in the rat kidney sample they were also processed by both kits using
the miRNA isolation method according to the manufacturer’s
instructions. Mouse kidney samples were processed using the RNeasy
Mini kit (Qiagen) with the inclusion of the DNA digestion step.
Transmission electron microscopy analysis
Rat kidney was fixed by intravascular perfusion with 2%
glutaraldehyde in 0.1 mol/l sodium cacodylate buffer, pH 7.4
(Electron Microscopy Sciences, Hatfield, PA, USA), and kidney
slices were further fixed overnight at 4 1C. The sample was rinsed in
0.1 mol/l sodium cacodylate buffer, post-fixed in 1% osmium
tetroxide in cacodylate buffer for 1 h at room temperature, rinsed in
buffer again, then rinsed in distilled water and stained, en bloc, in an
aqueous solution of 2% uranyl acetate for 1 h at room temperature.
The samples were rinsed in distilled water and dehydrated through a
graded series of ethanol to 100%. The samples were infiltrated with
Epon resin (Ted Pella, Redding, CA, USA) by overnight immersion
in a 1:1 solution of Epon:ethanol. The following day samples were
placed in fresh Epon for several hours and embedded in Epon
overnight at 60 1C. Thin sections were cut on a Reichert Ultracut E
ultramicrotome, collected on formvar-coated grids, and stained with
uranyl acetate and lead citrate. For microvesicles, samples were fixed,
1:1 with 4% paraformaldehyde in distilled water. Drops of 10ml were
pipetted onto formvar-coated 200 mesh gold grids and drawn off
after 1 min. Samples were rinsed twice with drops of distilled water.
Aqueous 2% phosphotungstic acid was applied (10 ml) for 10 s,
drawn off and rinsed once with distilled water. Samples were
examined in a JEOL JEM 1011 transmission electron microscope
(JOEL, Akishima, Tokyo, Japan) at 80 kV. Images were collected
using an AMT (Advanced Microscopy Techniques, Danvers, MA,
USA) digital imaging system.
RT-PCR analysis
Microvesicles isolated from human or mouse urine were subjected
to RNase and DNase digestion on the outside of the exosomes before
exosome lysis and RNA extraction. The extracted RNA underwent
two rounds of mRNA amplification using RiboAmp (Molecular
Devices, Sunnyvale, CA, USA). For the riboamplification in the first
round of the in vitro transcription step samples were incubated at
42 1C for 4 h, and for the second in vitro transcription step samples
were incubated at 42 1C for 6 h. Amplified RNA was denatured for
5 min at 65 1C and subjected to first-strand cDNA synthesis as
described in the Qiagen Omniscript protocol (Qiagen).
For human samples the PCR primers used were: ACTB UTR,
forward 50-GAAGTCCCTTGCCATCCTAA-30, reverse 50-GCTATCA
CCTCCCCTGTGTG-30; GAPDH EX, forward 50-ACACCCACTC
CTCCACCTTT-30, reverse 50-TGCTGTAGCCAAATTCGTTG-30;
NPHS2 UTR, forward 50-AACTTGGTTCAGATGTCCCTTT-30,
reverse 50-CAATGATAGGTGCTTGTAGGAAG-30; LGALS1 EX, for-
ward 50-GGAAGTGTTGCAGAGGTGTG-30, reverse 50-TTGATGGC
CTCCAGGTTG-30; HSPG2 UTR, forward 50-AAGGCAGGACT
CACGACTGA-30, reverse 50-ATGGCACTTGAGCTGGATCT-30;
CUBN EX, forward 50-CAGCTCTCCATCCTCTGGAC-30, reverse
50-CCGTGCATAATCAGCATGAA-30; LRP2 EX, forward 50-CAAAA
TGGAATCTCTTCAAACG-30, reverse 50-GTCGCAGCAACACTTTC
CTT-30; AQP1 UTR, forward 50-TTACGCAGGTATTTAGAAGCAG
AG-30, reverse 50-AGGGAATGGAGAAGAGAGTGTG-30; CA4 UTR,
forward 50-ATGATGGCTCACTTCTGCAC-30, reverse 50-TCATGCC
TAAAGTCCCACCT-30; CLCN5 EX, forward 50-GTGCCTGGTTA
CACACAACG-30, reverse 50-AGGATCTTGGTTCGCCATCT-30;
BDKRB1 UTR, forward 50-GTGGTTGCCTTCCTGGTCT-30, reverse
50-ATGAAGTCCTCCCAAAAGCA-30; CALCR UTR, forward 50-
ATTTTGCCACTGCCTTTCAG-30, reverse 50-ATTTTCTCTGGGT
GCGCTAA-30; SCNN1D UTR, forward 50-GCGGTGATGTACC
CATGCT-30, reverse 50-CTGAGGTGGCTAGGCTTGA-30; SLC12A3
EX, forward 50-AGAACAGAGTCAAGTCCCTTCG-30, reverse 50-
TATGGGCAAAGTGATGACGA-30; AQP2 UTR, forward 50-GCAG
TTCCTGGCATCTCTTG-30, reverse 50-GCCTTTGTCCTTCCCTA
ACC-30; ATP6V1B1 EX, forward 50-AGGCAGTAGTTGGGGAGG
AG-30, reverse 50-CGAGCGGTTCTCGTAGGG-30; SLC12A1 EX,
forward 50-CAGATGCAGAACTGGAAGCA-30, reverse 50-GGAAGG
CTCAGGACAATGAG-30. UTR refers to primers designed in the
UTR and EX refers to primers designed across exons. The PCR
protocol was 5 min at 94 1C; 40 s at 94 1C, 30 s at 55 1C, 1 min at
65 1C for 30 cycles; and for 4 min at 68 1C. For mouse samples the
primers used were:
AQP2, forward 50-GCCACCTCCTTGGGATCTATT-30, reverse
50-TCATCAAACTTGCCAGTGACAAC-30, and
V-ATPase B1 subunit, forward 50-CTGGCACTGACCACGGCT
GAG-30, reverse 50-CCAGCCTGTGACTGAGCCCTG -30.
The PCR protocol was 5 min at 94 1C; 40 s at 94 1C, 30 s at 55 1C,
1 min at 65 1C for 30 cycles; 4 min at 68 1C.
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Real-time PCR analysis of mouse studies
RNA extracted from mouse urinary microvesicles was denatured for
5 min at 65 1C and subjected to first-strand cDNA synthesis as
described in the Qiagen Sensiscript protocol (Qiagen, Maryland,
MD, USA). For the Sensiscript reverse transcription oligo-dT
primers were used at a final concentration of 1 mM (Applied
Biosystems, Foster City, CA, USA). The resulting cDNA was used in
the TaqMan PreAmp Master Mix Kit according to the manufac-
turer’s guidelines using 14 pre-amplification cycles (Applied
Biosystems). The pre-amplification product was then diluted 1:20
with 1TE buffer (Promega, Madison, WI, USA). The resulting
cDNA was then used as a template for real-time PCR according to
the Taqman Preamplification guide (Applied Biosystems). Mouse
kidney RNA concentration was measured on a SmartSpec 3000 (Bio-
Rad, Hercules, CA, USA) and all samples were diluted to 90 ng/ml.
Mouse kidney RNA was denatured for 5 min at 65 1C and subjected
to first-strand cDNA synthesis as described in the Qiagen
Omniscript protocol (Qiagen). In the Omniscript reverse transcrip-
tion oligo-dT primers were used at a final concentration of 1 mmol/l
(Applied Biosystems) and 1 ml of the resulting cDNA was then used
per well in the subsequent real-time PCR reaction. The real-time
PCR reaction was carried out using TaqMan Gene Expression Master
Mix and Expression Assays (Mouse GAPD Part Number 4352339E
and mouse Atp6v1b2 assay id Mm00431996_mH) on an ABI 7300
Real-Time PCR System (Applied Biosystems).
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